Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling

Area of Science:

• Neuroscience
• Endocrinology
• Pediatric Oncology

Background:

• Steroid-induced sleep disturbance is a common side effect in pediatric acute lymphoblastic leukemia (ALL) patients undergoing chemotherapy.
• Sleep disruption negatively impacts quality of life, neurodevelopment, and healing.
• Orexin neurons promote wakefulness, and their signaling is crucial for normal sleep behavior.

Purpose of the Study:

• To investigate the impact of corticosteroid treatment doses on the orexin system in rodents and children with ALL.
• To determine if the orexin pathway is implicated in steroid-induced sleep disturbances.

Main Methods:

• Rodents received repeated dexamethasone injections; orexin neural activity was measured.
• Cerebrospinal fluid (CSF) samples were collected from pediatric ALL patients before and during dexamethasone therapy.
• CSF orexin concentrations were analyzed to assess steroid impact.

Main Results:

• Orexin signaling markers, including neural output and receptor expression, remained unchanged in rodents treated with dexamethasone.
• No significant difference was observed in CSF orexin concentrations in children before and during dexamethasone therapy.
• Rodent and human orexin physiology appears largely preserved under high-dose dexamethasone.

Conclusions:

• High-dose dexamethasone does not significantly alter orexin physiology in rodents or humans.
• The orexin pathway is unlikely to be the primary cause of sleep disturbances associated with steroid treatment in pediatric ALL.
• Orexin receptor antagonists may not be a suitable therapeutic strategy for this specific sleep disorder.